VIRX (Viracta Therapeutics) Research & Development: $33.09 Mil (TTM As of Sep. 2024)


What is Viracta Therapeutics Research & Development?

Viracta Therapeutics VIRX Research & Development is $33.09 Mil as of Sep. 2024.

Research & Development is the aggregate amount of research and development expenses during the year. Viracta Therapeutics's Research & Development for the three months ended in Sep. 2024 was $7.18 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 was $33.09 Mil.

Viracta Therapeutics  (OTCPK:VIRX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Viracta Therapeutics Research & Development Related Terms

Viracta Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Viracta Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viracta Therapeutics Research & Development Chart

Viracta Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Research & Development
13.47 23.86 26.26 33.37

Viracta Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.16 9.41 9.96 6.55 7.18

Viracta Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $33.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $33.09 Mil mean?
Viracta Therapeutics (VIRX) has a Research & Development of $33.09 Mil as of Sep. 2024. Research and development expense is the total cost for research and development activities. View historical data on Viracta Therapeutics and its competitors.
Is Viracta Therapeutics' Research & Development too high?
Viracta Therapeutics' current Research & Development is $33.09 Mil.
How does Viracta Therapeutics' Research & Development compare to TSOI and CYTOF?
Viracta Therapeutics' Research & Development of $33.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Viracta Therapeutics and its competitors. Viracta Therapeutics's current Research & Development is $33.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viracta Therapeutics stock overvalued right now?
Viracta Therapeutics (VIRX) has a current Research & Development of $33.09 Mil. The current Research & Development is $33.09 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Viracta Therapeutics (VIRX), the current Research & Development is $33.09 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viracta Therapeutics Business Description

Address 2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.